Literature DB >> 12071781

Prescription-event monitoring in Japan (J-PEM).

Kiyoshi Kubota1.   

Abstract

In prescription-event monitoring in Japan (J-PEM), patients are identified by prescriptions in individual pharmacies where drugs are dispensed. The methodology is somewhat different to that used by the Drug Safety Research Unit in the UK, in that two questionnaires, one to the pharmacist and the other to the doctor are sent for each patient and the method of concurrent control is employed in J-PEM. In the data analysis, the list of events reported as a suspected reaction or a reason for stopping the drug is made to generate a signal. In addition, a signal may be generated for some events with the statistically significant difference of crude rates followed by the regression analysis or a follow-up study. In J-PEM, Medical Dictionary for Regulatory Activities (MedDRA) terminology is used for data entry and data analysis. Lowest level terms (LLTs) in MedDRA are used in data entry while a signal is generated using preferred terms (PTs). However, to generate a signal effectively, some PTs may be grouped as one term. In addition, if two terms are so similar, it may be instructed that one of those two terms is normally selected in data entry to avoid confusion. Many more PEM studies could be undertaken to determine if MedDRA can be used for effective signal generation, but the usefulness of MedDRA in J-PEM is still to be determined.

Entities:  

Mesh:

Year:  2002        PMID: 12071781     DOI: 10.2165/00002018-200225060-00008

Source DB:  PubMed          Journal:  Drug Saf        ISSN: 0114-5916            Impact factor:   5.606


  4 in total

1.  The use of a medical dictionary for regulatory activities terminology (MedDRA) in prescription-event monitoring in Japan (J-PEM).

Authors:  M Yokotsuka; M Aoyama; K Kubota
Journal:  Int J Med Inform       Date:  2000-07       Impact factor: 4.046

2.  Tabulation and analysis of pharmacovigilance data using the medical dictionary for regulatory activities.

Authors:  E Brown Bmedsci Mb Chb Mrcgp Ffpm; S Douglas Bsc
Journal:  Pharmacoepidemiol Drug Saf       Date:  2000-11       Impact factor: 2.890

3.  Pilot study of prescription-event monitoring in Japan comparing troglitazone with alternative oral hypoglycemics.

Authors:  K Kubota; E Kawabe; S Hinotsu; C Hamada; Y Ohashi; K Kurokawa
Journal:  Eur J Clin Pharmacol       Date:  2001 Jan-Feb       Impact factor: 2.953

4.  A design for prescription-event monitoring in Japan (J-PEM).

Authors:  K Kubota
Journal:  Pharmacoepidemiol Drug Saf       Date:  1999-10       Impact factor: 2.890

  4 in total
  3 in total

1.  Modified prescription-event monitoring studies: a tool for pharmacovigilance and risk management.

Authors:  Deborah Layton; Lorna Hazell; Saad A W Shakir
Journal:  Drug Saf       Date:  2011-12-01       Impact factor: 5.606

Review 2.  Pharmacovigilance during the pre-approval phases: an evolving pharmaceutical industry model in response to ICH E2E, CIOMS VI, FDA and EMEA/CHMP risk-management guidelines.

Authors:  Craig G Hartford; Kasia S Petchel; Hani Mickail; Susana Perez-Gutthann; Mary McHale; John M Grana; Paula Marquez
Journal:  Drug Saf       Date:  2006       Impact factor: 5.606

3.  Comparison of losartan with ACE inhibitors and dihydropyridine calcium channel antagonists: a pilot study of prescription-event monitoring in Japan.

Authors:  Kazuo Samizo; Eri Kawabe; Shiro Hinotsu; Tsugumichi Sato; Shigeru Kageyama; Chikuma Hamada; Yasuo Ohashi; Kiyoshi Kubota
Journal:  Drug Saf       Date:  2002       Impact factor: 5.606

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.